Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

  16 March 2020

The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed.

 

Author(s): Francesca Conradie, M.B., B.Ch., Andreas H. Diacon, M.D., Nosipho Ngubane, M.B., B.Ch., Pauline Howell, M.B., B.Ch., Daniel Everitt, M.D., Angela M. Crook, Ph.D., Carl M. Mendel, M.D., Erica Egizi, M.P.H., Joanna Moreira, B.Sc., Juliano Timm, Ph.D., Timothy D. McHugh, Ph.D., Genevieve H. Wills, M.Sc., et al
Healthy Patients  
Back


Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!